CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

This study is ongoing, but not recruiting participants.

First Received: March 29, 2001 Last Updated: June 23, 2005 History of Changes

Sponsored by:	National Center for Research Resources (NCRR)
Information provided by:	National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:	NCT00013806

Purpose

131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma. This is a dual institution, Phase II study of 131I-MIBG administered at the previously defined maximum practical dose of 18 mCi/kg to children with relapsed or refractory neuroblastoma.

Condition	Intervention	Phase
Neuroblastoma	Drug: 131I-MIBG	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

Resource links provided by NLM:

MedlinePlus related topics: Neuroblastoma

Drug Information available for: 3-Iodobenzylguanidine Iobenguane

U.S. FDA Resources

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor histopathology or elevated urine VMA with typical tumor cells in the bone marrow.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00013806

Locations

United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

National Center for Research Resources (NCRR)

More Information

No publications provided

Study ID Numbers:	NCRR-M01RR00240-1748
Study First Received:	March 29, 2001
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00013806 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):

Relapsed and refractory neuroblastoma

Study placed in the following topic categories:

Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
3-Iodobenzylguanidine
Neoplasms, Germ Cell and Embryonal

Neuroepithelioma
Neuroectodermal Tumors, Primitive, Peripheral
Neuroblastoma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Neuroectodermal Tumors, Primitive
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Neoplasms, Nerve Tissue
Enzyme Inhibitors
Pharmacologic Actions
Neuroblastoma

Neuroectodermal Tumors
Neoplasms
3-Iodobenzylguanidine
Neoplasms, Germ Cell and Embryonal
Therapeutic Uses
Neoplasms, Neuroepithelial
Neuroectodermal Tumors, Primitive, Peripheral
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on July 02, 2009